Skip to content Skip to menu

Industry partnerships educate doctors

Wednesday, 28 February 2018

Media Release

Medicines Australia (MA) is pleased to announce the release of the fourth biannual innovative medicines industry’s transfer of value data to nurses, doctors and other healthcare professionals.

Medicines Australia Chief Executive Mr Milton Catelin emphasised the importance of this initiative.

“This data symbolises the essential partnerships that industry has with the medical community and highlights our commitment to ensuring that practitioners are provided with the most up to date information about breakthrough medicines,” said Mr Catelin.

“These latest transparency reports provide clear information about payments or other support provided to healthcare professionals, so they can access the latest educational opportunities, attend world leading local and international conferences or symposia, or for their services as an expert,’

“By supporting ongoing education, companies can assist healthcare professionals to acquire the appropriate understanding and knowledge of innovative therapies to ensure they are used safely and appropriately by doctors and their patients.”

“These reports, along with previous rounds, also highlight some important data trends, namely, that participating medical practitioners have not ceased interacting with companies since reporting became mandatory,”

The data also shows that healthcare professionals from rural and regional Australia also receive support for their ongoing education, not just those in capital cities, and that year on year the figures are similar.”

“I once again congratulate MA members for embracing a level of openness and accountability with regards to their support for medical educational activities that is certainly not echoed in the wider pharmaceutical space,” said Mr Catelin.

Further information about the transparency requirements of the MA Code of Conduct and hyperlinks to each member company’s reports are available here.

MA encourages consumers to talk to their doctors if they would like to know more about their relationships with different companies and the benefits to patient health.


MORE INFORMATION: Natalie Wimmer – Communications Manager – 0450 728 660


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at